Anti-amyloid antibodies in Europe: Where are we now?

Juricic Nahal D, Mas P, Cegec I, Bego M, Domjanovic IK

Open source

DOI
10.1002/bcp.70526
Published
2026 Jun
Container
British journal of clinical pharmacology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/bcp.70526,
  title = {Anti-amyloid antibodies in Europe: Where are we now?},
  author = {Juricic Nahal D and Mas P and Cegec I and Bego M and Domjanovic IK},
  year = {2026},
  journal = {British journal of clinical pharmacology},
  doi = {10.1002/bcp.70526},
  url = {https://doi.org/10.1002/bcp.70526}
}

RIS

TY  - JOUR
TI  - Anti-amyloid antibodies in Europe: Where are we now?
AU  - Juricic Nahal D
AU  - Mas P
AU  - Cegec I
AU  - Bego M
AU  - Domjanovic IK
PY  - 2026
JO  - British journal of clinical pharmacology
DO  - 10.1002/bcp.70526
UR  - https://doi.org/10.1002/bcp.70526
ER  - 

APA

D, J. N., P, M., I, C., M, B., & IK, D. (2026). Anti-amyloid antibodies in Europe: Where are we now?. British journal of clinical pharmacology. https://doi.org/10.1002/bcp.70526

Source records